OncoMatch/Clinical Trials/NCT05230680
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
Is NCT05230680 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies ACHOP for t cell lymphoma.
Treatment: ACHOP — Induction treatment (every 3 weeks, total 6 cycles) * Azacitidine D-2, -1, 1 (level 1: 50mg/m2, level 2: 75mg/m2, level 3: 100mg/m2, level 4: 125mg/m2) * Cyclophosphamide 750mg/m2 d1 * Doxorubicin 50 mg/m2 d1 * Vincristine 1.4 mg/m2 (Max: 2 mg) d1 * Prednisolone 100mg PO d1-5 Maintenance treatment (every 4 weeks, total 12 cycles) * Azacitidine 75mg/m2 d1-5
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: short-term corticosteroids (for less than 8 days) prior to selection
Previously treated for T-cell lymphoma with immunotherapy or chemotherapy, except for short-term corticosteroids (for less than 8 days) prior to selection
Cannot have received: chemotherapy
History of chemotherapy for Hodgkin's or other non-Hodgkin's lymphoma in the last 5 years
Cannot have received: radiation therapy
Exception: localized to a single lymph node
Prior radiotherapy, except for those localized to a single lymph node
Cannot have received: doxorubicin (doxorubicin)
History of administration of doxorubicin at >200 mg/m²
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1,500/μl, platelets ≥100,000/μl (or anc ≥500/μl and platelets ≥50,000/ μl in the presence of bone marrow involvement)
Kidney function
serum cr ≤2.0mg/dl or egfr ≥ 30ml/min according to the cockroft-gault formula
Liver function
alt ≤2.5x upper limit of normal (uln) (or ≤5x uln in the presence of liver involvement), total bilirubin ≤2x uln (or ≤3x uln in the presence of liver involvement)
Cardiac function
lvef ≥45% on echocardiography or muga
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05230680 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 85 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages